New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
DiamondRock (DRH) downgraded to Neutral from Buy at ISI Group... Dynamic Materials (BOOM) downgraded to Neutral from Overweight at JPMorgan... Fresenius Medical (FMS) downgraded to Neutral from Buy at UBS... Humana (HUM) downgraded to Sell from Neutral at Citigroup... Jazz Pharmaceuticals (JAZZ) downgraded to Hold from Buy at Cantor... Juniper (JNPR) downgraded to Neutral from Overweight at Piper Jaffray... NII Holdings (NIHD) downgraded to Neutral from Outperform at Macquarie... Phillips 66 Partners (PSXP) downgraded to Neutral from Outperform at Credit Suisse... Safeway (SWY) downgraded to Neutral from Overweight at JPMorgan... Toll Brothers (TOL) downgraded to Market Perform from Outperform at Keefe Bruyette... Valero Energy Partners (VLP) downgraded to Neutral from Outperform at Credit Suisse... Volaris (VLRS) downgraded to Hold from Buy at Deutsche Bank... Vornado (VNO) downgraded to In-Line from Outperform at Imperial Capital... Martha Stewart (MSO) downgraded to Hold from Buy at Noble Financial... IZEA (IZEA) downgraded to Neutral from Buy at Merriman... Forest Oil (FST) downgraded to Market Perform from Outperform at Wells Fargo... Newmont Mining (NEM) downgraded to Hold from Buy at Argus... SeaChange (SEAC) downgraded to Neutral from Buy at Dougherty... InterMune (ITMN) downgraded to Market Perform from Outperform at Leerink... Solar Senior Capital (SUNS) downgraded to Hold from Buy at BB&T... DreamWorks Animation (DWA) downgraded to Underweight from Neutral at Piper Jaffray... ARIAD (ARIA) downgraded to Neutral from Buy at Chardan.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
September 25, 2015
13:51 EDTJAZZBMO's pharma predictions for rest of year include take on Mylan, Perrigo
BMO Capital analyst David Maris rolled out his rest of year predictions for the Specialty Pharmaceuticals space. Among them is his belief that Mylan (MYL) will be unsuccessful in acquiring Perrigo (PRGO). Perrigo will either be acquired by another company or make an acquisition itself, Maris tells investors in a research note. His other predictions include Jazz Pharmaceuticals (JAZZ) proving to be a good buying opportunity amidst the current negative sentiment and ZS Pharma (ZSPH) offering upside following the recent pullback given the potential for a near-term buyout and prospects for its "best in class drug for hyperkalemia" winning approval in 2016.
10:48 EDTDWAMorgan Stanley cautious on media, but sees several stocks punished too hard
Morgan Stanley cut its price targets on a number of media companies, citing the impact of cord cutting and skinny bundles. The firm also reduced its outlook for the pay-TV sector due to its belief that the adoption of skinny bundles will accelerate, while the outlook for cable TV ads has deteriorated slightly, given macro pressures. The firm kept a Cautious view on the media sector, but also identified several stocks in the space that it thinks have been punished too harshly by investors recently. WHAT'S NEW: TV networks in general, and cable networks in particular, have the highest margins in media and are encountering increased top and bottom line competitive pressures, Morgan Stanley analyst Benjamin Swinburne believes. On the top line, they are being hit by ratings and ad pressures as well as cord cutting and distribution consolidation, the analyst stated. Meanwhile, their profit is being hurt by the increased need to obtain new content and intensified competition for content from new sources like Netflix (NFLX) and Google's (GOOG) YouTube, Swinburne said. However, the analyst thinks that media stocks are "starting to get" cheap, given the leverage that many of the companies carry. Swinburne cuts his price target on 21st Century Fox (FOXA) to $31 from $37, on AMC Networks (AMCX) to $86 from $88, on CBS (CBS) to $46 from $56, on Time Warner (TWX) to $72 from $87 and on Viacom (VIAB) to $48 from $60. He kept Overweight ratings on Fox, AMC and CBS, an Equal Weight rating on Time Warner and an Underweight rating on Viacom. OVERDONE DECLINES: Swinburne believes that the declines in three media stocks - CBS, 21st Century Fox, and AMC Networks - have been overdone, while the decline in Comcast's (CMCSA) stock has also been excessive. CBS and 21st Century Fox are "best positioned for the skinny bundle" and have the cheapest valuations relative to their growth rates, Swinburne believes. Meanwhile, AMC Networks has "content momentum" and its EPS can exceed expectations, the analyst believes. Comcast is gaining share in the broadband Internet market, could take share in video soon, and has sufficient scale and offerings to benefit from the increased popularity of skinny bundles, according to the analyst, who kept an Overweight rating on the stock. The media sector could benefit from consolidation going forward, added Swinburne, who recommended that investors interested in buying potential takeover targets in the space focus on AMC Networks, MSG Networks (MSG) and Dreamworks Animation (DWA). He kept Overweight ratings on all three of those stocks. OTHERS TO WATCH: Besides Comcast, other pay TV companies include DISH Network (DISH) and Charter Communications (CHTR). PRICE ACTION: In early trading, Fox A shares lost 0.5% to $25.83, AMC fell 0.3% to $73.29, CBS added 0.2% to $41, Time Warner was little changed at $67.66 and Comcast A shares added 0.6% to $57.17.
06:39 EDTHUMAPA: Big insurance firm mergers could harm mental healthcare, Reuters says
Subscribe for More Information
September 24, 2015
15:52 EDTTOLOptions with increasing volume; RIG YNDX BLK BBBY TOL HES CC
Subscribe for More Information
10:01 EDTVLPOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: 8point3 Energy (CAFD) upgraded to Market Perform from Underperform at Avondale... AEGON (AEG) upgraded to Buy from Neutral at Goldman... AMC Networks (AMCX) upgraded to Buy from Hold at Evercore ISI... Citi ups Ralph Lauren (RL) to Buy on valuation, cost savings... Kate Spade (KATE) upgraded to Overweight from Equal Weight at Stephens... L'Oreal (LRLCY) upgraded to Buy from Hold at Societe Generale... Marriott (MAR) upgraded on historical performance, growth outlook at SunTrust... Monster Beverage (MNST) upgraded to Buy from Neutral at Goldman... Nimble Storage (NMBL) upgraded to Buy from Neutral at Longbow... Qualys (QLYS) upgraded to Neutral from Underperform at Macquarie... Ralph Lauren (RL) upgraded to Buy from Neutral at Citi... Trex Company (TREX) upgraded to Outperform from Neutral at Wedbush... Valero Energy Partners (VLP) upgraded on better than expected transaction at SunTrust.
08:32 EDTVLPValero Energy Partners upgraded on better than expected transaction at SunTrust
Subscribe for More Information
06:13 EDTVLPValero Energy Partners upgraded to Buy from Neutral at SunTrust
Subscribe for More Information
September 23, 2015
10:24 EDTJNPROptions with increasing implied volatility
Options with increasing implied volatility: SNCR PTCT SRPT AMZN CREE CMG ISRG QLIK SNKD BIIB JNPR
08:11 EDTHUMLeerink sees less political risk for Managed Care mergers after hearings
Subscribe for More Information
September 22, 2015
20:02 EDTHUMClinton vows $250 cap on monthly drug costs in blast against biotechs, insurers
Democratic presidential candidate Hillary Clinton railed against biotech companies as well as health insurers at a community health care forum in Iowa on Tuesday. Clinton began her speech by praising the Affordable Care Act, but quickly noted that she wants to strengthen it due to what she called the rising cost of prescription drugs. She explained, "Our pharmaceutical and biotechnology industries deserve credit... [But] too often, these drugs cost a fortune. Now, sometimes there is a good reason for that. Scientific breakthroughs are often the result of major investment... so it may makes sense, for a short period of time, to have to charge a lot of money for a drug. But when a drug has no competition, when there aren't any other treatments that can do what it does, pharmaceutical companies can charge astronomical fees far beyond anything that it would take to recoup their investment, and far beyond what they charge consumers anywhere else in the world outside of America." Referencing the recent criticism against Turing Pharmaceuticals, Clinton went on to say that "pharmaceutical companies that acquire an existing affordable drug that people rely on, and then turn around and charge a fortune for it, [are just betting] on the fact that desperate people will find some way to pay for it." Preemptively responding to questions of whether greater regulation will dampen investment, Clinton commented that "some people worry that my proposals will threaten innovation, but I have designed a plan that will do exactly the opposite... Under my plan, drug companies that want to keep getting federal support will have to redirect more of their profits into meaningful investments in research and development." Clinton also criticized incremental drug improvements, saying that "too often, so-called new drugs are really old drugs that have just been tweaked a little bit, but then they're marketed as breakthrough drugs and they're sold for high prices." The Democratic candidate went on to condemn advertising in the drug industry, remarking that "I also want to tackle direct to consumer advertising... Other countries ban these ads because they are so often misleading. But at the very least, we shouldn't be encouraging them with corporate write-offs... Under my plan, we will instead use that taxpayer money to fund innovation... I would also like to make sure any ads the drug industry does run are approved by the FDA." Moving more broadly onto Medicaid and health insurers, Clinton stated, "I believe Medicare should be able to negotiate for lower prices for its members... I will require drug companies to provide higher rebates for prescription drugs to low income Medicare patients, just like they have to do for Medicaid patients... I think the insurance companies need to be put on notice." Providing more concrete details of her plan, Clinton concluded, "I will cap out of pocket drug costs for working families. You won't have to pay more than $250 a month for covered medications... Particularly for people who have a chronic illness. Also under my plan, you will be able to import cheaper drugs from other countries legally. If the medicine you need costs less in Canada, you should be able to buy it from Canada or any other country that meets our safety standards... I will also make sure we have more generics on the market [by boosting funding for] the FDA's office of generic drugs."
14:52 EDTHUMAetna plans to raise Humana wages after merger, Bloomberg says
Aetna (AET) CEO Mark Bertolini plans to raise wages to $16 per hour for about 10,000 low-wage Humana (HUM) employees if the prospective merger of the two companies goes through, reports Bloomberg, citing written testimony at a U.S. Senate subcommittee hearing. "Our hope is these initiatives will help reduce employee turnover," explained Bertolini. Reference Link
14:32 EDTNEMNewmont CEO says not interested in buying Barrick U.S. assets, Reuters reports
Subscribe for More Information
10:36 EDTJNPRGoldman upbeat on telecom equipment, lukewarm on IT hardware
The telecom equipment sector has a number of positive catalysts, Goldman Sachs wrote in a note to investors today. The firm has a neutral view on the IT Hardware sector, however, noted the analyst team that took over coverage of the stocks in the space. WHAT'S NEW: Telecom equipment companies should benefit from spending on 100G wide area network upgrades between 2015 and 2017, Goldman analyst Simona Jankowski wrote. Also likely to boost the sector is the expansion of cloud providers' private networks, the analyst stated. The latter trend should produce a new market for the sector, Jankowski believes. Within the sector, she kept Buy ratings on Juniper (JNPR), Arris (ARRS) and Ciena (CIEN). The analyst, who has an Attractive view on the Telecom Equipment sector, has a Sell rating on shares of Infinera (INFN), however. WHAT'S NOTABLE: Jankowski views the IT hardware sector as a mixed bag. The sector's valuations are attractive, and it is generating strong free cash flow and robust capital returns, the analyst believes. However, it is being hurt by the shift to cloud computing and by foreign exchange fluctuations, Jankowski warned. Within the sector, she downgraded NetApp (NTAP) to Sell from Neutral and kept a Sell rating on Motorola Solutions (MSI). PRICE ACTION: In early trading, Jumiper declined 2% to $25.24, Arris gave back 1.8% to $26.40, Ciena dropped 2% to $21.77, Infinera fell 3.8% to $20.27, NetApp tumbled 4.5% to $29.80 and Motorola Solutions lost 1% to $66.30.
10:23 EDTJNPROptions with increasing implied volatility
Subscribe for More Information
08:37 EDTHUMAetna, Anthem CEOs set to testify to Senate committee, WSJ reports
Subscribe for More Information
07:34 EDTNEMDenver Gold Group to hold a forum
Subscribe for More Information
September 21, 2015
10:22 EDTARIAOptions with decreasing implied volatility
Options with decreasing implied volatility: ADXS CVC NWBO RPTP ATML QIHU ARIA LNG MBLY SCTY
07:52 EDTFMSBerenberg and Goldman Sachs to hold a conference
Subscribe for More Information
06:21 EDTNEMBarrick Gold seeing 'strong' interest in gold assets, Reuters reports
Subscribe for More Information
September 20, 2015
15:44 EDTSWYSafeway recalls cheese trays over possible listeria contamination
Safeway announced it is recalling certain "Flight of Cheese" trays prepared in store at Safeway which may contain recalled Yanni and Gopi brand cheese products due to possible listeria monocytogenes contamination. The products have been sold from Safeway stores in Ontario, Manitoba, Saskatchewan, Alberta and British Columbia. The Canadian Food Inspection Agency is conducting a food safety investigation, which may lead to the recall of other products, according to Safeway. There have been no reported illnesses in Canada associated with the consumption of these products, said the company.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use